A Peptoid “Antibody Surrogate” That Antagonizes VEGF Receptor 2 Activity

Division of Translational Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9185, USA.
Journal of the American Chemical Society (Impact Factor: 12.11). 05/2008; 130(17):5744-52. DOI: 10.1021/ja711193x
Source: PubMed


We report a two-color, cell-based screen to identify specific receptor-binding compounds in a combinatorial library of peptoids displayed on beads. We apply this strategy to the isolation of vascular endothelial growth factor receptor 2 (VEGFR2)-binding peptoids. A dimeric derivative of one of these lead compounds is shown to be an antagonist of VEGFR2 activity both in vitro and in vivo. This methodology provides a potentially general route to synthetic molecules that bind integral membrane receptors with affinities and specificities similar to those of antibodies, but which are far smaller and easier to make and manipulate.

Download full-text


Available from: Gomika Udugamasooriya
  • Source
    • "Structural studies (Herbert et al., 2013) suggest that the small molecule attains its selectivity by targeting an extracellular domain that is present only in the D2D3 region of FGF receptor (Fig. 7B). In addition to this small molecule example, there is evidence that the extracellular domains of RTKs can be allosterically targeted by peptide-mimetics, "peptoids," and antibodies (Fleishman et al., 2002; Udugamasooriya et al., 2008; Cazorla et al., 2010; Jura et al., 2011). 5. Antibody Modulation of Receptor Tyrosine Kinase Activity. The recent upsurge in interest in monoclonal antibodies that target RTKs and their associated signaling pathways is uncovering new mechanisms of allostery that involve different interaction domains on the receptor and even the cognate ligand. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Allosteric interactions play vital roles in metabolic processes and signal transduction and, more recently, have become the focus of numerous pharmacological studies because of the potential for discovering more target-selective chemical probes and therapeutic agents. In addition to classic early studies on enzymes, there are now examples of small molecule allosteric modulators for all superfamilies of receptors encoded by the genome, including ligand- and voltage-gated ion channels, G protein-coupled receptors, nuclear hormone receptors, and receptor tyrosine kinases. As a consequence, a vast array of pharmacologic behaviors has been ascribed to allosteric ligands that can vary in a target-, ligand-, and cell-/tissue-dependent manner. The current article presents an overview of allostery as applied to receptor families and approaches for detecting and validating allosteric interactions and gives recommendations for the nomenclature of allosteric ligands and their properties.
    Full-text · Article · Oct 2014 · Pharmacological reviews
  • Source
    • "In these examples, target binding peptide sequences have been incorporated directly into the protein monomers [18], or synthetic targeting agents have been installed using chemical bioconjugation techniques [25]. Although both strategies can be quite effective, the latter approach has the advantage of increased modularity, and it can be used with virtually any targeting agent, including aptamers [27], [28], peptoids [29], [30], and engineered protein binders [31], [32]. Our group has previously used this strategy to functionalize bacteriophage MS2 VLPs for targeted delivery [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thrombosis is the cause of many cardiovascular syndromes and is a significant contributor to life-threatening diseases, such as myocardial infarction and stroke. Thrombus targeted imaging agents have the capability to provide molecular information about pathological clots, potentially improving detection, risk stratification, and therapy of thrombosis-related diseases. Nanocarriers are a promising platform for the development of molecular imaging agents as they can be modified to have external targeting ligands and internal functional cargo. In this work, we report the synthesis and use of chemically functionalized bacteriophage MS2 capsids as biomolecule-based nanoparticles for fibrin imaging. The capsids were modified using an oxidative coupling reaction, conjugating ∼90 copies of a fibrin targeting peptide to the exterior of each protein shell. The ability of the multivalent, targeted capsids to bind fibrin was first demonstrated by determining the impact on thrombin-mediated clot formation. The modified capsids out-performed the free peptides and were shown to inhibit clot formation at effective concentrations over ten-fold lower than the monomeric peptide alone. The installation of near-infrared fluorophores on the interior surface of the capsids enabled optical detection of binding to fibrin clots. The targeted capsids bound to fibrin, exhibiting higher signal-to-background than control, non-targeted MS2-based nanoagents. The in vitro assessment of the capsids suggests that fibrin-targeted MS2 capsids could be used as delivery agents to thrombi for diagnostic or therapeutic applications.
    Full-text · Article · Jun 2014 · PLoS ONE
  • Source
    • "In order to substantially increase the number of compounds that could be used in such a screen, we first developed a protocol that allowed one-bead, one-compound (OBOC) libraries synthesized on hydrophilic TentaGel beads to be used directly in the screening step. Libraries of hundreds of thousands, or even millions, of peptoids are easily prepared in this format by splitand-pool solid-phase synthesis (Alluri et al., 2003; Figliozzi et al., 1996; Lam et al., 1991), and these libraries can be used productively in screening experiments using recombinant proteins (Lim et al., 2007; Xiao et al., 2007) or cells (Lau et al., 2002; Mikawa et al., 2004; Udugamasooriya et al., 2008) as targets. The strategy that we envisioned is shown in Figure 1A. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder of the central nervous system. In most NMO patients, autoantibodies to the water channel protein Aquaporin 4 (AQP4) are present at high levels and are thought to drive pathology by mediating complement-dependent destruction of astrocytes. Here, we apply recently developed chemical library screening technology to identify a synthetic peptoid that binds anti-AQP4 antibodies in the serum of NMO patients. This finding validates, in a well-defined human disease, that synthetic, unnatural ligands for the antigen-binding site of a disease-linked antibody can be isolated by high-throughput screening.
    Preview · Article · Mar 2013 · Chemistry & biology
Show more